Hyperbaric Oxygen Therapy is an advanced wound healing technology that can help patients suffering from a wide range of acute and chronic ophthalmological disorders and diseases. These include: decompression sickness, carbon monoxide poisoning with visual sequelae, arterial gas embolisms, ocular and periocular gas gangrene, central retinal artery occlusions, periocular necrotizing fasciitis, cerebro-rhino-orbital mucormycosis, radiation or mitomycin C-induced scleral necrosis, periorbital reconstructive surgery and radiation optic neuropathy, among others.
Select cases of post-surgical inflammation, Purtscher’s retinopathy, branch retinal artery occlusion with central vision loss, cystoid macular adema, and ischemic optic neuropathy, may also benefit from Hyperbaric Oxygen Therapy.
See the Research & Studies section below for detailed information related to your specialty.
How your patients will benefit from HBOT
- Increased oxygen levels in plasma
- Reduced inflammation
- Effective against invasive fungal infections
- IL1, IL6, and TNF alpha downregulation
- Bactericidal to anaerobic and aerobic bacteria including claustriium species and staph (including MRSA)
Did You Know?
Hyperbaric Oxygen Therapy Reduces Tissue Hypoxia. By increasing tissue oxygenation, optimal cellular functioning can be achieved. More oxygen created more energy for accelerated repair and enhanced regeneration of tissue. Hypoxic tissue (low oxygen levels) can lead to cell death and is a primary cause of most major health conditions, including stroke, heart attack, cancer, diabetes complications and many more.
Our experienced clinical team is available to help you identify appropriate candidates for Hyperbaric Oxygen Therapy and to answer any additional questions about HBOT or our facilities. You deserve the best – our mission is to achieve patient success through personalized, innovative, and compassionate care that enhances your healing potential. We do so at the lowest possible out-of-pocket cost for your patients, with only one copay and/or less coinsurance than at a hospital-based HBOT program.